Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting()()()

BACKGROUND: To evaluate the efficacy and toxicities of regorafenib plus irinotecan, dose-escalated on the basis of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping, in previously heavily treated metastatic colorectal cancer (mCRC) and the prognostic values of EGFR expression, KRAS...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Cheng-Jen, Huang, Ching-Wen, Chang, Tsung-Kun, Tsai, Hsiang-Lin, Su, Wei-Chih, Yeh, Yung-Sung, Chen, Po-Jung, Wang, Jaw-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2018
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307535/
https://www.ncbi.nlm.nih.gov/pubmed/30594039
http://dx.doi.org/10.1016/j.tranon.2018.12.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307535/
https://www.ncbi.nlm.nih.gov/pubmed/30594039
http://dx.doi.org/10.1016/j.tranon.2018.12.003

Ejemplares similares